Pharmaceutical company in
Eysins

AliveDx Suisse SA

Since 2013 · 101–500 empl.·5.0(3)

The core activity of AliveDx is the development and manufacture of innovative solutions for clinical diagnostics, particularly in the field of blood banks and automated testing platforms. The company focuses on creating products that make laboratory work more efficient and improve decision-making in clinical practice. The main products include the blood bank reagent portfolio 'Alba' and the automated testing platform 'MosaiQ'.

Matrixsanos Sàrl

Since 1996 · 1–10 empl.

Matrixsanos Sàrl manufactures chromopuncture instruments, ultrasonic devices to deter martens, and instruments for producing silver and copper colloids. The company supplies specialized products for therapists and for personal use.

Merck Performance Materials (Suisse) SA

Since 2003 · 101–500 empl.

Merck Performance Materials (Suisse) SA is part of the Merck Group and operates in Switzerland across the Healthcare, Life Science and Electronics businesses. The company develops and supplies products, technologies and services for research, medical applications, and electronics and semiconductor uses.

Asceneuron SA

Since 2012 · 11–20 empl.

Asceneuron SA develops orally administered therapies for neurodegenerative diseases. It researches small-molecule drugs intended to inhibit abnormal protein aggregation in the brain, including in Alzheimer’s disease, Parkinson’s disease and tauopathies.

Fresenius Kabi SwissBioSim GmbH

Since 2017 · 1–10 empl.

Fresenius Kabi SwissBioSim GmbH is an affiliated company of Fresenius Kabi in the biopharmaceutical sector. Fresenius Kabi’s Biopharma business develops, manufactures and supplies biosimilars, biological medicines highly similar to approved reference medicines.

Pharmotech SA

Since 2018 · 1–10 empl.

The core activity of Pharmotech SA is the research and development of medical products based on plant-based active ingredients, particularly CBD, to combat multi-resistant bacteria (MDR-MRSA). The company focuses on researching and developing innovative solutions to combat bacteria such as Pseudomonas Aeruginosa and Staphylococcus Aureus.

SpringWorks Therapeutics Europe Sàrl

Since 2024 · 21–50 empl.

The company is a biotechnology company specializing in the development of drugs for the treatment of cancer, particularly rare cancer types such as Multiple Myeloma, Desmoid tumors and NF1-PN.

Chord Therapeutics SA

Since 2014 · 1–10 empl.

Augusta Life Sciences SwissCo Sàrl

Since 2025 · 1–10 empl.

Augusta Life Sciences SwissCo Sàrl is among the companies in BD’s Biosciences & Diagnostic Solutions business acquired by Waters.